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Abstract
Spondyloarthritides, or SpA, form a cluster of chronic inflammatory
diseases with the axial skeleton as the most typical disease
localisation, although extra-articular manifestations such as
intestinal inflammation may frequently occur during the course of
the disease. This review summarises recent progress in our
understanding of the immunopathogenesis of SpA with special
emphasis on the cellular constituents considered to be responsible
for the initiation and/or perpetuation of inflammation. There are
several arguments favouring a role for haematopoietic cells in the
pathophysiology of spondyloarthritis, including HLA-B27-asso-
ciated dendritic cell disturbances, HLA-B27 misfolding properties
and T helper 17 cells. In addition, recent studies have pointed
toward a pivotal role for stromal cells. A major challenge, however,
remains to determine how recently identified genetic associations
such as interleukin-23 receptor polymorphisms may influence
cellular targets in spondyloarthritis.
Introduction
Spondyloarthritides, or SpA, are a group of chronic
inflammatory diseases that affect about 0.5% of the Western
population. The most typical disease localisation is the axial
skeleton, more specifically the spine and sacroiliac joints.
Additionally, enthesitis or peripheral arthritis of the large joints
of the lower limbs frequently occurs. Extra-articular manifes-
tations are also a common feature in SpA. They include anterior
uveitis, psoriasis and inflammatory bowel disease (IBD).
SpA refers to a cluster of disorders that were formerly
considered separate disease entities. It comprises ankylosing
spondylitis (AS), reactive arthritis (ReA), IBD-associated
arthritis and some forms of psoriatic arthritis (PsA). This
grouping was based on three important considerations: (a)
the different disease phenotypes could consecutively mani-
fest in the same patient, (b) overlaps that make it impossible
to distinguish between the different disorders are often seen,
and (c) different disorders can affect different members of the
same family. Apart from the presence of shared environmental
factors, this familial aggregation can be explained for the
most part by an important hereditary component in the
pathogenesis of the disease. First-degree relatives of SpA
patients are 40 times more likely than the general population
to develop SpA [1,2].
Features of inflammation in
spondyloarthritides
For many years, an intimate relationship between mucosal
and joint inflammation has been established (reviewed in [3]).
Pioneering studies by Mielants and Veys [4] demonstrated
that about 60% of SpA patients displayed microscopic signs
of inflammation in the colon and/or ileum which were
unrelated to clinical gastrointestinal symptoms. This illustrates
that SpA is a disorder in which many different types of organs
may be involved. Extensive studies have been undertaken to
characterise the nature of the inflammatory infiltrates in
synovial tissue, entheses as well as extra-articular tissues
such as colon and/or ileum. Bone marrow inflammation may
also occur during the course of SpA and is even considered
by some investigators to be one of the principal and initial
events [5]. This inflammation can be focal or diffuse. It can be
located in both sacral and iliac bones and consists of an
accumulation of mononuclear cells. These cells were
reported to contain plenty of T lymphocytes that can be
CD4+ as well as CD8+ [6-9].
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In the overlaying synovium and enthesis, the predominant
cells are macrophages that often carry the scavenger recep-
tor CD163 at the cell surface [10,11]. Intriguingly, in the gut,
signs of acute inflammation, characterised by infiltration of
polymorphonuclear cells, as well as of chronic inflammation,
characterised by a mixed macrophage-lymphocyte infiltrate,
can be found, and accordingly, subgroups of gut
inflammation related to SpA have been described [4,12]. The
macrophages in the gut are also frequently CD163+ [13].
Remarkably, even in the absence of histological signs of
active inflammation, the frequency of dendritic cells (DCs)
and T cells was still found to be increased in ileal mucosa of
SpA patients [14]. In all of the tissues involved in the SpA
phenotype, an extensive neovascularisation is present [15]. A
striking feature of SpA is that the joint involvement combines
features of bone destruction versus bone remodelling, which
distinguishes it from other inflammatory rheumatic disorders,
notably rheumatoid arthritis (RA) [16]. In the remaining part of
this review, we will summarise recent progress in our
understanding of the immunopathogenesis of SpA, with
special emphasis on the cellular constituents considered to
be responsible for the initiation and/or perpetuation of
inflammation in SpA.
The crucial role for mesenchymal cells in
tumour necrosis factor-dependent
inflammation
The strongest experimental evidence aimed at defining
cellular targets for inflammation in SpA was found in the
TNFΔARE mouse model, characterised by a 69-base pair
deletion of the tumour necrosis factor (TNF) AU-rich elements
(AREs) from the mouse genome. This leads to increased
steady-state TNF mRNA levels in both haematopoietic and
stromal tissues as well as a diminished translational silencing
of the TNF message. The animals spontaneously develop an
inflammatory disease characterised by Crohn-like ileitis,
sacroiliitis, enthesitis and peripheral arthritis, making this
model very attractive for studying SpA [17]. Several
mechanistic studies were undertaken to determine the
cellular source providing pathogenic TNF loads as well as the
cellular targets of pathogenic TNF.
Although gut and joint inflammation coexist in this model, it
appeared that some striking differences do exist in the
regulation of Crohn-like ileitis as opposed to peripheral
arthritis. Hence, in the absence of mature B and T cells,
peripheral arthritis still occurred whereas the intestinal pheno-
type was almost completely prevented [17], suggesting that
intestinal inflammation in this model depends on adaptive
immune responses. An additional study revealed that a
redundancy in the cellular source of TNF-driving Crohn-like
ileitis exists and that both myeloid cells or T lymphocytes are
sufficient to provide pathogenic TNF loads [18].
To address which cell types respond to chronic TNF
overexposure, bone marrow engraftment experiments were
carried out to assess the role of TNF receptor I (TNFRI) in the
development of arthritis and IBD in these mice. Transfer of
TNFΔARE TNFRI–/– bone marrow into wild-type irradiated
recipients resulted in an IBD and arthritis phenotype similar to
that of TNFΔARE-reconstituted wild-type mice. By contrast,
when TNFΔARE bone marrow was transferred to TNFRI–/–
recipients, no signs of joint inflammation were found, although
gut inflammation was present. This suggests that radiation-
resistant, tissue stroma-residing cells are required TNF
targets for the induction of arthritis. However, for the
development of IBD, radiation-sensitive, bone marrow-derived
cells are equally important and sufficient targets for
pathogenic TNF. These findings clearly indicate the existence
of independent, yet redundant, cellular pathways operating
downstream of TNF in the pathogenesis of IBD [18,19].
Furthermore, activation of mesenchymal cell types from gut
and joint appeared prior to the onset of clinically overt
disease. A formal proof for the importance of stromal cells
was shown recently by Armaka and colleagues [19] using
Cre/loxP-mediated TNFRI expression in mesenchymal cells.
In the presence of chronic TNF overexposure, signalling
through TNFRI in synovial fibroblasts and intestinal
myofibroblasts appears to be sufficient to develop combined
gut and joint pathologies, a hallmark of SpA. However, it
remains to be determined why stromal cells are preferentially
activated at certain localisations (for example, enthesis,
sacroiliac joints) in SpA rather than at other sites.
Contribution to inflammation of
haematopoietic cells
Influence of HLA-B27-associated pathological events
The most important genetic contribution to SpA comes from
the HLA-B27 gene, which accounts for approximately 30% of
the hereditability [1,2]. In the HLA-B27/human beta 2
microglobulin (Huβ2m) transgenic rat model, only genetically
predisposed strains (Lewis or Fisher rats) with a high copy
number of the transgene develop an inflammatory syndrome
consisting of spondylitis, sacroiliitis, peripheral arthritis,
enterocolitis and psoriasiform skin lesions [20-22]. Hence,
this model can be used to study SpA. The HLA-B27 subtype
integrated in the transgene locus is the HLA-B*2705
subtype, which is the common ancestor of the closely related
HLA class I allotypes and which has been positively associa-
ted with AS in multiple population studies [23]. Bone marrow
engraftment experiments within this model showed that
disease arises as a consequence of a high level of expression
of the transgenes in cells of haematopoietic origin [24].
Role of antigen-presenting cells and modulation by HLA-B27
Recently, a hypothesis that implies aberrant formation of
immunological synapses was proposed. Additional cell
transfer experiments in this model suggested an indispen-
sable and provocative role for HLA-B27, a major histo-
compatibility complex (MHC) class I molecule, in modulating
CD4+ T-cell activation [25].
In response to antigen recognition and following adhesion
between DCs and T cells, T-cell receptor signalling in
cooperation with costimulatory signals mediated by CD28 is
critical for initiation and stabilisation of the immunological
synapse [26]. By contrast, much less is known about the
antigen-independent immunological synapse formation, in
which a majority of naive CD4+ T cells exhibit a Ca2+ res-
ponse upon contact with DCs in the absence of nominal
antigen. It can be expected that costimulatory molecules also
play a prominent role in this process [27]. Because of the
lack of a demonstrable role of MHC class I-restricted CD8+
T cells, new hypotheses to explain the pathogenicity of
HLA-B27 in this model are based on these non-antigen-
specific mechanisms as opposed to the classic arthritogenic
peptide-based hypotheses.
In those antigen-independent systems, HLA-B27 transgenic
DCs (HLA-B27 DCs) showed a dramatically decreased
capacity to stimulate T cells. This was not related to altered
chemokine production by HLA-B27 DCs but resulted rather
from the formation of fewer conjugates between HLA-B27
DCs and T cells. Blocking costimulatory molecules (CD86 on
DCs or CD28, CD2 and CD4 on T cells) inhibited a greater
proportion of the conjugates formed with control DCs than
with HLA-B27 DCs, indicating that HLA-B27 DCs failed to
use several T-cell costimulatory molecules involved in
synapse formation.
This defective DC function is not secondary to chronic inflam-
mation, because it was also found in premorbid disease-
prone rats. In contrast, DC function was not significantly
reduced in disease-resistant lines bearing a low copy number
of the HLA-B27/Huβ2m transgene or a high copy number of
the HLA-B7/Huβ2m transgene [27,28].
All together, these findings indicate that defective DC function
is a feature particularly related to HLA-B27 and is dependent
on the number of copies of the HLA-B27/Huβ2m transgene.
Hacquard-Breban and colleagues [27,28] proposed that DC
function may be a causal mechanism for SpA-like develop-
ment in this transgenic rat model, perhaps by affecting the
induction or maintenance of MHC class II-restricted regulatory
T cells. Intriguingly, when DC-induced allogeneic T-cell
proliferation was compared among different transgenic lines
and crosses with distinct levels of susceptibility to SpA-like
disease, stimulatory capacity was inversely correlated with
disease susceptibility [29]. However, formal proof of this
indispensable role of DC dysfunction in SpA pathogenesis still
needs to be established in non-transgenic animal models or
using adoptive transfer experiments. Evidently, it remains to be
determined whether these effects of HLA-B27 on DC function
can also be found in humans.
HLA-B27 misfolding and formation of homodimers
Another hypothesis regarding immunopathogenesis relates to
the structural capacities of the HLA-B27 molecule, which
consists of a trimer of heavy-chain, β2 microglobulin and
short peptide. The heavy chain has the tendency to misfold,
to accumulate in the endoplasmic reticulum (ER) and to form
disulfide-linked homodimers, thereby inducing ER stress.
This accumulation may cause an unfolded protein response
(UPR), which induces profound changes in the cellular
metabolism, including inhibition of general translation but also
transcriptional upregulation of molecular chaperone genes
[30,31]. The contribution of HLA-B27 to spondyloarthritis
through misfolding and formation of heavy-chain dimers was
recently challenged in the transgenic rat model (as well as in
human disease).
The introduction of additional Huβ2m in a disease-prone line
resulted in an increased prevalence and severity of arthritis
with no effect on diarrhea since this developed in all rats
independently of extra Huβ2m. In addition, the introduction of
additional Huβ2m in a previously healthy HLA-B27/Huβ2m
line (lower transgene copy numbers) induced an even more
severe inflammatory syndrome: rats more frequently deve-
loped a more severe arthropathy, with more clinical and histo-
pathological similarities to SpA (increased prevalence of axial
disease) than in the original model. Moreover, in contrast to
disease-prone lines, no evidence of gut inflammation was
observed. However, in accordance with the original hypo-
thesis, less HLA-B27 heavy-chain misfolding and dimer
formation in combination with lower BiP (binding protein)
mRNA (marker of UPR triggering) levels was seen in these
rats compared with the same line when no additional Huβ2m
was introduced [22]. However, care needs to be taken when
interpreting these results. Folding properties and UPR
triggering of stimulated splenocytes rather than macrophages
were analysed in this study. Turner and colleagues [30]
pointed out that the biological consequences of HLA-B27
misfolding may differ considerably depending on the cell
type. On the one hand, appropriate stimulation of HLA-B27
transgenic macrophages resulted in HLA-B27 upregulation,
accumulation of misfolded heavy chains and consequently
upregulation of UPR target gene expression. On the other
hand, stimulated HLA-B27 transgenic splenocytes revealed
little activation of the UPR, which was consistent with minimal
HLA-B27 upregulation. Thus, the degree to which additional
Huβ2m may reduce the UPR caused by HLA-B27 up-
regulation has not been formally established yet. Furthermore,
folding properties of HLA-B27 subtypes in humans showed
incomplete correspondence to AS, indicated by the fact that
one of the four AS-associated HLA-B27 subtypes folded with
the same high efficiency as the non-disease-associated
subtypes [32]. It is not yet clear whether misfolded molecules
participate in AS pathogenesis.
HLA-B27 as cell surface ligand for immunomodulatory
receptor families
Intriguingly, HLA-B27 in classical (trimer of heavy chain, β2
microglobulin and short peptide) as well as β2m-independent
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forms may also act as cell surface ligands for immuno-
modulatory receptor families called the killer cell immunoglob-
ulin (Ig) receptors (KIRs) and the leukocyte Ig-like receptors
(LILRs)/Ig-like transcripts (ILTs). KIRs and ILTs modulate
activation of other immune receptors [33,34]. Peripheral
blood and synovial fluid leukocytes from patients with
spondyloarthritis were shown to express cell surface HLA-
B27 heavy-chain dimers [35]. In addition, DCs of an HLA-
B27+ individual displayed induction of dimer formation on
appropriate stimulation [36]. These β2 microglobulin-
independent homodimer forms bind a distinct pattern of the
KIRs and LILRs compared with classical HLA-B27 complexes
[34]. Moreover, KIR3DL2-expressing natural killer (NK) and
CD4 T cells are expanded in the periphery and synovial fluid
of patients with HLA-B27-associated arthritis [37]. Interest-
ingly, KIR3DL2 ligation by HLA-B27 homodimers inhibited
NK-cell and T-cell clone interferon-gamma production [33].
These differences in binding, expression and function of
classical HLA complexes on the one hand and β2 micro-
globulin-independent forms on the other could be involved in
the pathogenesis of SpA.
Is spondyloarthritides a T helper 17-mediated disease?
Recently, the role of haematopoietic interleukin-17 (IL-17)-
producing T cells, the T helper 17 (Th17) cells, has been
raised in a wide variety of autoimmune diseases. These cells
typically express the IL-23 receptor (IL-23R) on their mem-
brane (reviewed in [38]). In addition, recent studies in IBD
[39], psoriasis [40] and most importantly AS [41-43] show
an important genetic contribution for polymorphisms in the
gene that codes for this IL-23R. Thus, the active poly-
morphisms in the IL-23R gene could indicate an important
role for this pathogenic T-cell subset in the development and
maintenance of AS. IL-23 by itself does not contribute to
early Th17 differentiation. However, it favours the expansion
and maintenance of this pathogenic T-cell subset [38,44].
This suggests that IL-17-producing T cells in SpA patients
could abnormally expand under the influence of IL-23.
Recently, it was also shown that the expression of CCR6
receptor, with CCL20 as its ligand, selectively identified
healthy-control peripheral blood CD4+ T cells producing
IL-17 [45].
Intriguingly, Jandus and colleagues [46] found increased
numbers of Th17 cells in the peripheral blood of PsA and AS
patients compared with RA patients and healthy controls.
These cells were more differentiated than their RA and
healthy control counterparts. In addition, CCR6+ cells were
more efficient in the production of IL-17 as compared with
their CCR6– counterparts. However, no significant differences
were observed in the frequency of Th17 cells among the
CCR6+ population in healthy controls and arthritis patients.
Recently, several groups have investigated the levels of IL-17,
IL-23 and CCL20 cytokines in serum and/or synovial fluid
from SpA patients. Melis and colleagues [47] reported no
significant differences in serum and synovial fluid levels of
IL-17 in non-PsA SpA patients with peripheral arthritis versus
controls, whereas Wendling and colleagues [48] showed
elevated serum levels in an AS patient population and Singh
and colleagues [49] showed elevated synovial fluid levels in a
cohort of patients with ReA and undifferentiated spondylo-
arthritis. Importantly, it was shown that CCL20 is capable of
attracting effector memory T cells, especially Th17 cells [50].
Of interest, we found that synovial fluid CCL20 levels were
elevated greatly over the serum levels [47], suggesting a true
chemotactic role for CCL20 in attracting this pathogenic
T-cell subset to the SpA joint.
Interestingly, an apparent paradoxical relationship between
TNF and the IL-23/IL-17 pathway appears to exist. In SpA
patients, for example, serum levels of p40 IL-12/23 did not
differ significantly from controls and these levels did not
change after TNF blockade treatment in contrast to systemic
parameters of inflammation [51]. These results were con-
firmed by Melis and colleagues [47] using a more specific
p19 IL-23 assay. By contrast, in the TNFΔARE mouse model of
SpA, an increased frequency of Th17 cells was recently
reported. Elevated levels of IL-17-producing CD4 T cells in
the terminal ileum of these mice were observed compared
with controls [52], although it is unclear whether the disease
itself can be attenuated by IL-17 blockade. In addition, the
putative relationship between TNF and IL-23 in this model
has not been explored yet.
IL-23 seems to be involved in subclinical gut inflammation
seen in AS patients as well. Ciccia and colleagues [53]
reported that IL-23 was markedly upregulated at the mRNA
and protein levels in the terminal ileum in comparison with
healthy controls. However, this finding was not associated
with a well-defined Th17 response since upregulation of
IL-17 and the IL-17-inducing cytokines IL-6 and IL-1β was not
seen.
Recently, the contribution of IL-17 was also assessed in
proteoglycan-induced arthritis, an SpA model dependent
upon immunisation with aggrecan. Although spondylitis – a
hallmark of SpA – was not assessed, peripheral disease
appeared to occur equally well in the presence or absence of
IL-17 [54]. This indicates that peripheral SpA-associated
arthritis is not IL-17-dependent in this model.
In summary, although some data point toward an involvement
of haematopoietic Th17 cells in SpA pathogenesis, the
current knowledge is too limited to draw firm conclusions.
Clearly, more studies are required to evaluate the contribution
of Th17 cells in SpA-associated inflammation. Particularly, the
biological role of IL-23R polymorphisms on survival and
expansion of Th17 cells is still an open question. In addition,
the significance of CCL20 to this Th17 system or to the
immunopathogenesis of SpA in general is not clear at
present.
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Conclusions and prospects for the future
Although the cause of SpA is unknown, it is generally
accepted that SpA is a multifactorial disease in which a
disturbed interplay occurs between the immune system and
environmental factors on a predisposing genetic background.
Several trails linking the diverse sites of inflammation in SpA
have been followed during the past decades. They involve
aberrant migration of intestinal lymphocytes or mononuclear
cells, particularly macrophages, but neither of these
hypotheses has been formally proven. Recent studies have
shed new insight into the putative role of an old and intriguing
player in SpA pathogenesis, HLA-B27, which displays
aberrant folding properties and can form ER and cell surface
homodimers. To date, however, it is not clear whether
misfolded molecules participate in AS pathogenesis. Other
research groups focus on the role of HLA-B27 in affecting
DC function in an antigen-independent manner. However,
formal proof that DCs are major drivers in SpA pathogenesis
is currently lacking. The most convincing experimental
breakthrough in defining responsible cellular targets in SpA
pathogenesis points toward stromal cells. Hence, TNFRI
expression on mesenchymal cells can phenocopy the entire
disease spectrum from a TNF-driven model of SpA.
Nonetheless, several important questions remain to be
addressed. The role of novel identified associations such as
the IL-23R – important for Th17 expansion and maintenance –
will have to be explored, especially as many of the associated
single-nucleotide polymorphisms were associated with a
protection against disease.
In conclusion, there is ample evidence that bone marrow as
well as stromal cells seem to be involved in SpA patho-
genesis. However, the interaction of these cell types remains
to be established, especially in human SpA. Furthermore, the
potential combined action of HLA-B27 and IL-23R poly-
morphisms in the pathogenesis of SpA will require a co-
ordinated approach with geneticists as well as immuno-
logists. Hence, all of the identified predisposing genes largely
affect adaptive immune responses. With the availability of the
various mouse engineering tools that allow these questions to
be addressed in a sophisticated manner, it is clear that
exciting times for SpA research lie ahead.
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